Home News Covaxin: The First Covid-19 Vaccine Research in India, Reaches Human Trial
Covid-19 Update
  • World 19,125,425
    World
    Confirmed: 19,125,425
    Active: 6,140,050
    Recovered: 12,271,361
    Death: 714,014
  • USA 4,999,746
    USA
    Confirmed: 4,999,746
    Active: 2,286,195
    Recovered: 2,551,453
    Death: 162,098
  • Brazil 2,873,304
    Brazil
    Confirmed: 2,873,304
    Active: 754,975
    Recovered: 2,020,637
    Death: 97,692
  • India 2,025,338
    India
    Confirmed: 2,025,338
    Active: 606,320
    Recovered: 1,377,384
    Death: 41,634
  • Russia 871,894
    Russia
    Confirmed: 871,894
    Active: 180,931
    Recovered: 676,357
    Death: 14,606
  • Spain 354,530
    Spain
    Confirmed: 354,530
    Active: 326,030
    Recovered: ?
    Death: 28,500
  • UK 308,134
    UK
    Confirmed: 308,134
    Active: 261,721
    Recovered: ?
    Death: 46,413
  • Pakistan 281,863
    Pakistan
    Confirmed: 281,863
    Active: 19,770
    Recovered: 256,058
    Death: 6,035
  • Bangladesh 249,651
    Bangladesh
    Confirmed: 249,651
    Active: 102,521
    Recovered: 143,824
    Death: 3,306
  • Italy 249,204
    Italy
    Confirmed: 249,204
    Active: 12,694
    Recovered: 201,323
    Death: 35,187
  • Turkey 237,265
    Turkey
    Confirmed: 237,265
    Active: 10,921
    Recovered: 220,546
    Death: 5,798
  • Germany 215,100
    Germany
    Confirmed: 215,100
    Active: 9,651
    Recovered: 196,200
    Death: 9,249
  • France 195,633
    France
    Confirmed: 195,633
    Active: 83,155
    Recovered: 82,166
    Death: 30,312
  • Canada 118,417
    Canada
    Confirmed: 118,417
    Active: 6,507
    Recovered: 102,947
    Death: 8,963
  • China 84,528
    China
    Confirmed: 84,528
    Active: 837
    Recovered: 79,057
    Death: 4,634
  • Singapore 54,555
    Singapore
    Confirmed: 54,555
    Active: 6,497
    Recovered: 48,031
    Death: 27
  • Réunion 671
    Réunion
    Confirmed: 671
    Active: 74
    Recovered: 592
    Death: 5

Covaxin: The First Covid-19 Vaccine Research in India, Reaches Human Trial

by sambit
25 views
first covid-19 vaccine research in india
5
(2)

The Covid-19 effect is experienced by countries all across the world and the vaccine research to fight the pandemic is on the rise. Researchers and scientists all aroudn the globe are making every possible effort to develop a vaccine with an intention to create a shield as protection against the novel coronavirus.

India is also moving on the same track, as Covaxin, the first vaccine candidate from the country, reaches human trial. The human trial was initiated last week. The research and trial were started by the Post-Graduate Institute of Medical Sciences in Rohtak and All India Institute of Medical Sciences in Patna. The vaccine is developed by Bharat Biotech, a reputed pharmaceutical company based in Hyderabad in collaboration with ICMR (Indian Council of Medical Research) and NIV (National Institute of Virology). The biotech company got approval from the DCGI (Drug Controller General of India) to get started with phase 1 and phase 2 of human clinical trials of the candidate vaccine.

Check out the facts about the indigenous vaccine to fight against Covid-19

  • Covaxin is derived from a strain of the coronavirus that was isolated by the NIV, Pune. An inactivated vaccine was developed by Bharat Biotech at Genome Valley in Hyderabad, where its high containment facility is located.
  • The company announced, “Once the vaccine is injected into a human, it has no potential to infect or replicate since it is a killed virus. It just serves to the immune system as a dead virus and counts an antibody response towards the virus.”
  • It was at AIIMs, Patna, that the human trials of the candidate vaccine started. The medical institute chose 10 volunteers for the experiment.
  • To believe the many reports released, the first dose of Covaxin would be given to keenly observe the participants. The second dose would only be given in a time interval of fo 14 days. After the two doses, the volunteers would be checked for any side-effects of the candidate vaccine, Covaxin.
  • Covid-19 vaccine, Covaxin was under the pre-clinical testing stage that was carried out on animals to ensure its safety. Earlier, the pharmaceutical company said, Results from these studies have been promising and show extensive safety and effective immune responses.”
  • A total number fo 12 institutes were selected by ICMR for these trials, including AIIMs in Patna and Delhi. Moreover, NIMS (Nizam’s Institute of Medical Sciences) in Hyderabad, also received a letter from the ICMR to become one of the trial sites. Institutes having dedicated clinical pharmacology departments were chosen for the Covaxin trials.
  • Bill Gates said, “India has a lot of capacity there — with the drug and vaccine companies that are huge suppliers to the entire world. You know, more vaccines are made in India than anywhere — starting with Serum Institute, that’s the largest.”
  • In the two phases of the trial process. Around 1100 people will be tested with Covaxin. The pharmaceutical company, Bharat Biotech, has decided to enroll almost 375 individuals for the first phase of human trials. Based on the results, they will plan to enroll around 750 individuals for the second trial.
  • Another human trial process is initiated in the Post-Graduate Institute of Medical Sciences, Rohtak on 17th July. As per the words of the health minister of Haryana, Anil Vij, “Three subjects were enrolled today. All have tolerated the vaccine very well.”
  • As per the words of Balram Bhargava, the Director General of ICMR, “From India’s perspective, we have two vaccine candidates. We are trying all out efforts to fast-rack it and it is the moral duty that there should not be a delay not even by a day for regulatory clearances for these vaccines so that we can break the transmission of the virus as soon as possible.”

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 2

No votes so far! Be the first to rate this post.

You may also like

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More